CPSC Exempts Powder Form of 2 Drugs from Child-Resistant Packaging
The Consumer Product Safety Commission has issued a final rule, effective July 22, 2011, which amends its child-resistant packaging requirements to exempt powder formulations of two oral prescription drugs, colesevelam hydrochloride (currently marketed as Welchol®) and sevelamer carbonate (currently marketed…
Sign up for a free preview to unlock the rest of this article
Export Compliance Daily combines U.S. export control news, foreign border import regulation and policy developments into a single daily information service that reliably informs its trade professional readers about important current issues affecting their operations.
as Renvela®), which are indicated to reduce elevated LDL cholesterol levels and improve glycemic control in adults with type 2 diabetes mellitus, and for the control of elevated serum phosphorus in chronic kidney disease patients on dialysis, respectively. The rule exempts these prescription drug products on the basis that child-resistant packaging is not needed to protect young children from serious injury or illness.